Investor disappointment as vaccines again come up short, despite the Q3 beat
30/10/24 -"Even the better-than-expected Q3 results failed to impress investors, as GSK’s key vaccines fell short of the street’s estimates, causing worries for future growth. Nonetheless, other areas ..."
Pages
66
Language
English
Published on
30/10/24
You may also be interested by these reports :
11/03/26
BioNTech’s full-year results revealed sales surpassing expectations, although the operating loss was higher than anticipated. The 2026 sales guidance ...
11/03/26
While we acknowledge the upcoming HIV patent expiries (c.17% of sales) starting 2027-28, we remain encouraged by GSK’s execution ability as it ...
06/03/26
We have incorporated the 2025 reported figures and added a new forecast year (2028) to our model. Consequently, we have reduced the out-year sales ...
05/03/26
The Q4 results fell somewhat short of expectations, as Life Science and Healthcare witnessed decent growth, whereas the quarter was tough for ...